Delivery Order SPE2DB20D1004-SPE2DB25F1701
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,095.26 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,478.60 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 21, 2025, with a completion date of August 22, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) under a firm fixed price contract valued at $3,328.73. The award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency awarded a delivery order valued at $8,009.57 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity). This is a firm fixed-price, non-set-aside contract with a completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was competitively selected...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,792.03 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on July 23, 2025, with completion scheduled for July 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply vehicle running through...
- The Defense Logistics Agency awarded a $5,017.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of September 5, 2025. This non-set-aside competitive award was issued to the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $52,500.45. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,900.70 to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg on August 15, 2025, with completion expected by August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,645.19 to AmerisourceBergen Drug Corp for GEMTESA 75 mg tablets (90-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price contract, classified as a non-set-aside competitive award, represents a direct procurement under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $61,502.26. This non-set-aside competitive award is categorized as a delivery order, with an ultimate completion date of July 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25F1701Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,479.31 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count), with an ultimate completion date of September 4, 2025. The contract, awarded on September 3, 2025, utilizes firm fixed-price pricing under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the supply of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. This award represents routine pharmaceutical procurement through DLA's Medical Supply Chain, supporting the Defense Health Agency and other federal healthcare systems. Gemtesa (mirabegron) is a prescription medication used in the treatment of overactive bladder, reflecting the diverse therapeutic domains covered under AmerisourceBergen Drug Corp's federal contract portfolio. AmerisourceBergen Drug Corp's consistent receipt of non-set-aside, competitively awarded contracts demonstrates its established capability to meet federal procurement requirements for critical medical supplies across multiple therapeutic categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 9/3/25 |